DEA Places Cannabinoid Into Schedule II

The Drug Enforcement Administration is placing the newly approved drug lasmiditan in Schedule V of the Controlled Substances Act, it said in an interim final rule. Effective Jan. 31, lasmiditan, which was granted approval by the Food and Drug Administration in October, is subject to new registration, labeling, recordkeeping, and import and export requirements. DEA is accepting comments on the rule until March 2.